Live pricing and vendor scores across 72 vendors.
Updated weekly · Finnrick + Janoshik labs · No vendor pays for ranking
Showing 28 of 28 peptides
Next-generation triple-agonist peptide (GLP-1, GIP, glucagon).
24 vendors · typical 4-12 mg weekly
A dual GLP-1 and GIP receptor agonist.
22 vendors · typical 2.5-15 mg weekly
A copper peptide complex naturally present in human plasma.
61 vendors · typical 1-3 mg 2-3x weekly
A synthetic growth hormone-releasing hormone.
42 vendors · typical 1-2 mg daily
A synthetic peptide derived from a protein found in the stomach.
60 vendors · typical 250-500 mcg daily
A combination of two peptides: CJC-1295, a synthetic peptide that acts as a growth hormone-releasing hormone analog, and Ipamorelin, a selective growth hormone secretagogue.
41 vendors · typical 100-200 mcg each, 1-2x daily
A synthetic version of thymosin beta-4, a naturally occurring peptide.
59 vendors · typical 2-5 mg per week
A selective growth hormone secretagogue that stimulates growth hormone release.
63 vendors · typical 200-300 mcg 1-2x daily
A synthetic long-acting analog of growth hormone-releasing hormone (GHRH).
55 vendors · typical In published human pharmacokinetic trials, CJC-1295 with DAC was studied at single subcutaneous doses of roughly 1 to 60 mcg/kg, with weekly dosing reflecting its multi-day half-life. The no-DAC form (Modified GRF 1-29) is short-acting and is commonly studied at around 100 mcg per administration, often dosed daily.
A long-acting glucagon-like peptide-1 (GLP-1) receptor agonist.
20 vendors · typical 0.25-2.4 mg weekly
A powerful combination of BPC-157, TB-500, and GHK-Cu designed for maximum recovery and healing with synergistic tissue regeneration.
10 vendors · typical Per component guidelines
A beauty-focused combination for skin, hair, and aesthetic improvements with comprehensive anti-aging support.
36 vendors · typical Per component guidelines
A synthetic peptide (Bremelanotide) that acts on melanocortin receptors in the central nervous system.
48 vendors · typical 0.5-2 mg as needed
Nicotinamide adenine dinucleotide, a coenzyme essential for cellular energy production and DNA repair.
43 vendors · typical 50-100 mg 2-3x weekly
A synthetic peptide that stimulates melanocortin receptors.
41 vendors · typical 250-500 mcg 2-3x weekly
A synthetic peptide derived from the brain.
46 vendors · typical 250-500 mcg daily
43 vendors · typical 300-600 mcg daily
A modified fragment of human growth hormone.
39 vendors · typical 300-600 mcg daily
A growth hormone-releasing hormone analog that stimulates natural growth hormone production.
43 vendors · typical 200-500 mcg before bed
A modified form of insulin-like growth factor 1 (IGF-1) that has a longer half-life.
39 vendors · typical 20-50 mcg daily
A naturally occurring peptide involved in immune system function.
39 vendors · typical 750 mcg - 1.6 mg twice weekly
A synthetic peptide that may influence the pineal gland and telomerase activity.
45 vendors · typical 5-10 mg per cycle (10-20 days)
A synthetic peptide derivative that may enhance cognitive function.
2 vendors · typical 1-5 mg daily
A 16 amino acid mitochondrial derived peptide encoded within the 12S rRNA region of the mitochondrial genome.
47 vendors · typical In research contexts, commonly explored at roughly 5 to 10 mg per week, often split across multiple administrations to account for its short half life. Evidence is largely preclinical with only early small human data, and dosing is not standardized.
A tripeptide (lysine, proline, valine) that forms the C-terminal fragment of alpha-MSH, a hormone with immunomodulatory activity.
44 vendors · typical In research contexts, commonly cited at roughly 200 to 500 mcg per day, with route-dependent variation and higher figures sometimes discussed for oral use. Oral dosing on an empty stomach is often discussed for gut-focused research. These are research figures, not medical guidance.
A long-acting synthetic analog of amylin, a hormone released by the pancreas that signals fullness.
25 vendors · typical In published human research, doses up to 2.4 mg once weekly have been studied, typically reached through gradual dose escalation in dose-finding trials. Cagrilintide is not an approved drug, and these figures reflect research settings only.
A dual GLP-1 and glucagon receptor agonist derived from the gut hormone oxyntomodulin, engineered with a fatty acid chain for long acting once weekly dosing.
9 vendors · typical In clinical research, administered once weekly subcutaneously with gradual dose escalation, reaching maintenance doses up to roughly 4.8 mg per week in obesity trials.
A synthetic dual GLP-1 and glucagon receptor agonist peptide, also known by the codes IBI362 and LY3305677.
7 vendors · typical In clinical research, administered once weekly with dose escalation, commonly at 4 mg, 6 mg, or 9 mg per week. This is research dosing context only and not a usage recommendation.